EPL Limited – Merger with Indovida India Private Limited
Date: 29 Mar 2026
Source: Board meeting outcome (Regulation 30 disclosure)
1. Transaction Overview
- Type: Scheme of amalgamation (merger by absorption) of Indovida India Private Ltd into EPL Limited.
- Effective Structure: EPL will issue 286 fully paid‑up equity shares (₹2 face value) for every 10,000 shares (₹10 face value) held by Indovida shareholders.
- Key Agreements Signed:
- Merger Implementation Agreement (MIA)
- Shareholders’ Agreement (SHA)
- Transition Services Agreement (TSA)
- Regulatory Approvals Required: NCLT, SEBI, Competition Commission of India, BSE & NSE, and requisite shareholder/creditor consents.
2. Financial Highlights (FY‑2025)
| Metric | EPL Limited | Indovida India |
|---|---|---|
| Turnover (₹ Cr) | 4,568 | 3,809 |
| Net‑worth (₹ Cr) | 1,717 | 6,459 |
Combined FY‑2025 turnover: ~₹8,377 cr
Combined net‑worth: ~₹8,176 cr
The share exchange ratio was derived from a joint valuation report (BDO & D&P) and a fairness opinion from Ernst & Young Merchant Banking Services, confirming an arm‑length transaction.
3. Shareholding Impact
- Pre‑merger (fully diluted):
- Promoters: 25.97% (8,44,79,781 shares)
- Public: 74.03% (24,08,29,927 shares)
- Post‑merger (fully diluted):
- Promoters: 68.37% (34,87,01,552 shares)
- Public: 31.63% (16,13,35,842 shares)
- Related parties:
- Indorama Netherlands B.V. (IVL) holds 24.44% of EPL and 99.99% of Indovida; will become a promoter after the merger.
- Epsilon Bidco Pte. Ltd. (promoter) holds 25.97% of EPL.
- Board composition: SHA grants Epsilon the right to nominate 1 director and IVL at least 3 directors.
4. Strategic Rationale
- Product & Market Expansion: Broader portfolio of extruded/laminated tubes, caps, closures across beauty, pharma, food, home‑care segments.
- Geographic Diversification: Combined footprint enhances presence in existing and new regions.
- Synergies & Cost Savings: Expected operational, organizational and financial efficiencies through resource pooling and automation.
- Capital Allocation: Integrated cash‑management and capital deployment framework.
- Human Capital: Access to a larger talent pool and leadership capabilities.
5. Key Agreements Details
Merger Implementation Agreement (MIA)
- Sets out the mechanics of the merger, conditions precedent (approvals, acquisition of Indovida Netherlands B.V. stake), stand‑still obligations, and timeline.
Shareholders’ Agreement (SHA)
- Governs rights of Epsilon and IVL, including board nominations and reserved matters requiring their consent.
Transition Services Agreement (TSA)
- IVL‑affiliated IVGSL will provide support services for 5‑10 years at cost. Annual fee caps: USD 1.03 m (Part A) and USD 1.37 m (Part B). No special governance rights arise from TSA.
6. Risks & Considerations
- Regulatory Clearance: Any delay or denial from NCLT, SEBI, CCI or stock exchanges could postpone or cancel the merger.
- Integration Risk: Merging two sizable operations may pose challenges in systems, culture, and supply‑chain alignment.
- Related‑Party Exposure: Significant stake held by IVL raises governance and conflict‑of‑interest scrutiny.
- Liquidity Impact: Reduced public float may affect share liquidity and market perception.
- Synergy Realisation: Expected cost savings and revenue uplift are contingent on successful execution of integration plans.
7. Outlook
The merger positions EPL as a larger, more diversified packaging leader with a stronger balance sheet and expanded market reach. While execution and regulatory risks remain, the strategic benefits and validated valuation support a moderately positive outlook for shareholders.
Prepared for investors on 29 Mar 2026.